nonvir
gene
deliveri
skelet
muscl
one
first
applic
gene
therapi
went
clinic
mainli
skelet
muscl
easili
access
tissu
local
gene
transfer
nonvir
vector
rel
safe
low
immunogen
track
record
howev
plasmid
dna
nake
complex
variou
chemistri
turn
moder
effici
human
inject
local
ineffici
toxic
case
inject
system
number
clinic
applic
initi
howev
base
transgen
adapt
good
local
impact
andor
wide
physiolog
outcom
ie
strong
humor
cellular
immun
respons
follow
introduct
dna
vaccin
neuromuscular
diseas
seem
challeng
nonvir
vector
nevertheless
local
product
therapeut
protein
may
act
distantli
inject
site
andor
hydrodynam
perfus
safe
plasmid
remain
viabl
basi
nonvir
gene
therapi
muscl
disord
cachexia
well
peripher
neuropathi
skelet
muscl
act
effect
platform
longterm
product
secret
therapeut
protein
system
distribut
introduct
dna
vaccin
elicit
strong
humor
cellular
immun
respons
review
see
convers
treatment
hereditari
neuromuscular
diseas
particularli
challeng
nonvir
vector
among
issu
follow
size
muscl
tissu
repres
half
total
mass
organ
poor
access
profound
muscl
peripher
nerv
progress
tissu
remodel
along
natur
histori
muscl
diseas
activ
process
necrosisregener
fibrosislipidosi
braun
afmtelethon
evri
cedex
franc
email
sbraun
afmtelethonfr
hand
nonvir
vector
bear
interest
advantag
recombin
virus
nonvir
vector
made
plasmid
dna
nake
complex
varieti
versatil
molecul
cation
lipid
polym
well
character
structur
finetun
mostli
nonimmunogen
provid
carri
protein
motif
allow
repeat
administr
chronic
diseas
compar
easi
produc
larg
scale
less
limit
size
constraint
leav
potenti
deliv
widetyp
genet
materi
larg
kb
far
beyond
size
code
sequenc
dystrophin
cdna
duchenn
muscular
dystrophi
nonvir
vector
remain
function
long
period
time
skelet
muscl
episom
plasmid
dna
persist
life
rodent
mani
year
larger
anim
deliv
low
turnov
tissu
includ
brain
spinal
cord
heart
muscl
review
see
synthet
vector
construct
substitut
viral
vector
deliv
therapeut
gene
mani
drug
human
principl
base
selfassembl
supramolecular
complex
often
electrostat
interact
posit
charg
vector
dna
neg
charg
phosphat
residu
complex
dna
condens
compact
less
expos
nucleas
degrad
among
cation
lipidand
polymerbas
system
extens
studi
earli
studi
dna
encapsul
neutral
anion
liposom
without
chang
structur
liposom
ratio
cation
charg
liposom
neg
charg
dna
usual
control
size
complex
typic
rang
nm
quasispher
particl
order
often
multilamellar
organ
posit
total
charg
enabl
effici
interact
neg
residu
cell
membran
intern
cell
occur
mainli
endocytosi
pathway
system
biodistribut
nonvir
vector
depend
upon
capabl
escap
blood
vessel
target
tissu
vector
must
small
enough
less
nm
cross
vascular
endotheli
cell
gain
access
surround
tissu
furthermor
also
design
ignor
contrast
viral
vector
nonvir
gene
transfer
elicit
larg
extent
activ
intak
process
therefor
sophist
vector
may
need
facilit
cellular
uptak
appropri
intracellular
process
transgen
signific
develop
artifici
complex
combin
differ
function
improv
gene
transfer
mani
cation
liposom
normal
accompani
neutral
lipid
dioleoylphosphatidylethanolamin
dope
cholesterol
dope
frequent
use
fuse
lipid
expos
low
ph
endosom
trigger
releas
associ
dna
cytosol
popular
modif
use
ligand
bind
peg
variou
target
approach
investig
includ
incorpor
peptid
antibodi
sugar
lipid
vesicl
facilit
tissu
target
review
see
howev
associ
compon
result
complex
structur
requir
thorough
formul
galen
studi
cell
entri
intracellular
barrier
may
impair
success
gene
deliveri
vector
need
escap
endosom
lysosom
membran
avoid
degrad
plasmid
dna
endosom
releas
dna
cation
polyplexbas
vector
may
base
physic
disrupt
neg
charg
endosom
membran
direct
interact
cation
complex
protonspong
phenomenon
result
osmot
swell
endosom
membran
ruptur
follow
releas
polyplex
cytoplasm
addit
fusogen
helper
lipid
dope
facilit
format
destabil
hexagon
phase
endosom
membran
enhanc
gene
express
promot
releas
dna
endosom
compart
fig
mention
major
cytoplasm
plasmid
fail
reach
nucleu
due
cytoplasm
nucleas
contrast
short
nucleic
acid
oligonucleotid
diffus
freeli
plasmid
dna
import
nucleu
activ
transport
process
via
nuclear
pore
complex
receptor
protein
includ
importin
ran
nuclear
local
signal
design
peptid
link
plasmid
dna
facilit
nuclear
import
review
see
number
therapeut
concept
explor
human
use
less
refin
nonvir
gene
deliveri
system
view
therapi
genet
disord
immunolog
disord
today
despit
number
sophist
chemistri
nonvir
vector
complet
satisfactori
transfer
gene
muscl
tissu
follow
system
administr
mani
complex
show
excel
transfect
activ
cell
cultur
perform
well
presenc
serum
activ
vivo
remain
least
log
magnitud
less
effect
viral
vector
therapeut
dose
requir
high
concentr
complex
besid
rel
larg
size
mani
synthet
vector
often
nm
main
obstacl
use
synthet
complex
via
system
deliveri
aggreg
instabl
toxic
includ
neg
charg
nake
plasmid
dna
polynucleotid
deliv
either
directli
combin
physic
method
ultrasound
electropor
complex
variou
chemic
entiti
cation
lipid
polym
b
uptak
pathway
involv
either
fusion
muscl
cell
membran
receptor
clathrin
caveola
pinocytosisdepend
endocytosi
follow
endosom
format
escap
endosom
degrad
nuclear
import
plasmid
dnapolynucleotid
transgen
express
propens
captur
mononuclear
phagocyt
system
lead
rapid
clearanc
phagocyt
cell
liver
spleen
lung
bone
marrow
particl
readili
aggreg
concentr
increas
toxic
often
link
colloid
instabl
synthet
vector
result
interact
molecul
biolog
fluid
lead
larg
aggreg
aggreg
gener
ineffect
gene
deliveri
agent
absorb
onto
surfac
circul
red
blood
cell
embol
microvasculatur
prevent
reach
intend
target
cell
opson
process
also
activ
complement
system
one
innat
immun
mechan
foreign
particl
within
bloodstream
turn
activ
phagocytosi
initi
inflammatori
respons
skelet
muscl
possess
poorli
permeabl
tight
endotheli
mayb
less
case
chronic
inflam
tissu
layer
highli
regul
microcircul
implic
one
would
expect
particul
system
distribut
easili
blood
circul
skelet
muscl
thu
prospect
nonvir
particul
vector
widespread
distribut
system
circul
limit
present
one
system
deliveri
attempt
initi
neuromuscular
diseas
indic
hereditari
inclus
bodi
myopathi
singl
patient
intraven
perfus
lipoplex
compassion
trial
patient
show
sign
increas
sialic
acidrel
protein
stabil
declin
muscl
strength
administr
vector
directli
target
tissu
avoid
obstacl
encount
system
deliveri
howev
approach
remain
hamper
diffus
limit
immun
cell
clearanc
interstiti
region
target
organ
inde
transgen
express
follow
direct
intramuscular
needl
deliveri
complex
often
local
region
close
inject
site
impli
dispers
colloid
particl
within
muscl
critic
issu
need
basic
studi
effect
formul
dispers
within
solid
tissu
skelet
muscl
nevertheless
poor
effici
remain
compat
applic
requir
low
level
therapeut
protein
genet
vaccin
cancer
peripher
limb
ischemia
tabl
interestingli
retrograd
transport
seem
obtain
gene
express
found
peripher
central
nervou
system
follow
intramuscular
administr
deliveri
therapeut
gene
peripher
neuron
upon
peripher
minim
invas
intramuscular
administr
polymer
nanoparticl
shown
feasibl
anim
model
nake
dna
manufactur
costeffect
manner
stabl
materi
store
room
temperatur
long
period
time
follow
lyophil
compos
bacteri
plasmid
contain
cdna
therapeut
gene
transcript
control
variou
eukaryot
continu
regulatori
element
bacteri
origin
replic
allow
product
bacteria
strong
promot
may
requir
optim
express
mammalian
cell
promot
deriv
virus
cytomegaloviru
cmv
simian
viru
use
howev
viral
deriv
promot
cmv
promot
may
suitabl
applic
chronic
diseas
illustr
neg
impact
inflammatori
cytokin
tumor
necrosi
thu
musclespecif
altern
cmv
promot
propos
desmin
promoterenhanc
control
express
cytoskelet
protein
desmin
creatin
kinas
promot
even
vaccin
vaccin
immun
respons
obtain
shown
compar
magnitud
mice
immun
dna
vaccin
contain
nonspecif
promot
clinic
efficaci
safeti
chronic
diseas
applic
may
necessari
maintain
appropri
level
gene
product
order
prevent
toxic
abl
modul
resum
transgen
express
respons
diseas
evolut
immun
problem
artifici
system
control
gene
base
two
element
chimer
transcript
factor
respond
small
induc
even
electr
field
artifici
promot
compos
multipl
bind
site
transcript
factor
follow
minim
promot
induc
gene
express
system
use
endogen
element
respond
exogen
signal
stress
cytokin
heat
metal
ion
hypoxia
howev
neither
musclespecif
induc
promot
absenc
induct
devoid
leaki
activ
hypomethyl
bacteri
cpg
sequenc
maintain
plasmid
dna
backbon
promot
element
helper
immun
respons
short
period
induct
antidna
antibodi
gener
may
howev
advantag
view
genet
vaccin
alon
primingboost
regimen
viral
vector
follow
serendipit
demonstr
transgen
express
skelet
muscl
inject
nake
dna
wolff
plasmid
dna
use
extens
varieti
indic
uptak
express
numer
transgen
demonstr
variou
speci
follow
intramuscular
administr
nake
dna
express
peak
around
day
follow
slow
decreas
prolong
steadi
state
year
case
nonimmunogen
transgen
longterm
express
probabl
link
postmitot
state
skelet
muscl
persist
administ
genet
materi
extrachromosom
episom
element
effici
plasmid
gene
transfer
skelet
muscl
tissu
direct
inject
low
cell
nuclei
remain
confin
inject
site
along
needl
track
across
speci
decreas
plasmid
size
nevertheless
nake
plasmid
dna
administr
use
anim
model
provid
system
sourc
therapeut
protein
genet
vaccin
pathogen
tumor
cell
therapeut
angiogenesi
later
case
local
gene
deliveri
focal
lesion
peripher
vasculatur
product
highli
activ
hormon
ideal
suit
use
intramuscular
percutan
vector
deliveri
human
intramuscular
inject
nake
plasmid
encod
angiogen
factor
hgf
use
small
number
patient
critic
limb
ischemia
demonstr
promis
clinic
efficaci
treatment
peripher
arteri
diseas
ischem
pain
ischem
ulcer
affect
limb
reliev
markedli
improv
trial
tabl
importantli
plasmidbas
preclin
clinic
trial
result
good
safeti
record
tabl
metaanalysi
clinic
trial
patient
total
local
administr
proangiogen
growth
factor
vegf
fgf
hgf
use
plasmid
viral
gene
transfer
intraarteri
intramuscular
inject
show
despit
promis
result
singl
studi
clear
benefit
could
identifi
peripher
arteri
diseas
patient
irrespect
diseas
sever
local
inject
nake
dna
evalu
muscl
regener
approach
myostatin
propeptid
gene
gun
deliveri
genet
motoneuron
disord
later
case
smn
induct
mous
spinal
muscular
atrophi
model
observ
follow
intramuscular
inject
tetanu
toxin
c
fragment
plasmid
artifici
spontan
regener
muscl
fiber
display
higher
still
limit
effici
transfect
physic
method
electr
ultrasound
puls
ballist
gene
gun
either
creat
transient
pore
cell
membran
increas
passiv
diffus
shown
improv
gene
transfer
skelet
muscl
puls
paramet
type
materi
use
ie
needl
versu
extern
appli
plate
electrod
critic
import
select
electrosonopor
defin
area
use
microbubbl
contrast
agent
show
increas
deliveri
skelet
muscl
allow
therapeut
angiogenesi
chronic
ischem
skelet
muscl
undetect
tissu
damag
slightli
higher
risk
random
integr
plasmid
dna
genom
dna
may
also
seen
still
limit
penetr
genet
materi
tissu
obtain
rang
cm
widespread
deliveri
larg
deep
muscl
remain
challeng
muscl
damag
inflamm
induc
method
peak
around
day
resolv
week
postinject
immun
respons
potenti
occur
therefor
strategi
may
suitabl
alreadi
inflam
tissu
dmd
muscl
high
level
gene
express
limb
diaphragm
muscl
achiev
rapid
inject
nake
dna
larg
volum
via
locoregion
hydrodynam
intravascular
deliveri
blood
inflow
outflow
block
surgic
use
extern
tourniquet
endothelium
muscl
continu
nonfenestr
show
low
permeabl
macromolecul
includ
plasmid
dna
hydrodynam
pressur
induc
extravas
inject
dna
probabl
expand
endothelium
therebi
make
pore
access
dna
entri
mechan
plasmid
dna
uptak
muscl
cell
still
clear
may
involv
lowaffin
receptormedi
nonspecif
process
procedur
safeti
support
larg
bodi
data
collect
mice
rat
dog
nonhuman
primat
edema
caus
inject
fluid
resolv
within
h
even
minim
sign
observ
muscl
toxic
clear
within
week
postinject
hind
limb
perfus
procedur
rather
quick
simpl
techniqu
may
appli
chronic
diseas
muscl
chronic
diseas
anemia
base
success
preclin
studi
use
mdx
mous
golden
retriev
muscular
dystrophi
grmd
dog
model
duchenn
muscular
dystrophi
posit
express
though
low
safeti
outcom
phase
trial
intramuscular
inject
myodi
fulllength
dystrophin
plasmid
duchenn
patient
first
complet
gene
transfer
clinic
trial
neuromuscular
diseas
ground
set
human
clinic
trial
use
myodi
forearm
duchenn
patient
dose
escal
studi
singlelimb
perfus
salin
carri
nine
adult
muscular
dystrophi
intraven
analgesia
studi
led
fan
et
al
demonstr
feasibl
safeti
limb
volum
upper
extrem
young
adult
muscular
dystrophi
perfus
limb
volum
associ
shortliv
physiolog
chang
peripher
nerv
without
clinic
correl
one
subject
studi
use
lower
cuff
pressur
nonhuman
primat
studi
mm
hg
vs
mm
hg
nonhuman
primat
studi
mdx
mous
grmd
dog
model
duchenn
dystrophi
nonhuman
primat
minim
volum
need
effici
nake
dna
limb
perfus
limb
volum
wherea
arteri
limb
perfus
turn
safe
grmd
dog
person
data
shown
ten
consecut
nake
dna
limb
perfus
everi
day
appear
safe
dystroph
mice
dog
even
though
headtohead
comparison
would
necessari
studi
suggest
gene
transfer
higher
diseas
muscl
wildtyp
anim
also
notic
highest
transfect
effici
found
nonhuman
primat
limb
muscl
express
report
gene
follow
singlelimb
perfus
therefor
limb
perfus
nake
dna
remain
valid
approach
treat
limb
dystroph
muscl
altern
viral
vector
seroposit
patient
indic
requir
larg
transgen
region
gene
transfer
ex
vivo
approach
use
genecorrect
stem
cell
nonvir
vector
also
explor
human
artifici
chromosom
hac
vector
capac
carri
larg
genom
loci
replic
segreg
autonom
without
integr
host
genom
hac
vector
contain
entir
human
dystrophin
gene
dyshac
nativ
regulatori
element
allow
dystrophin
express
level
similar
nativ
dystrophin
isoform
express
level
sinc
stabli
maintain
episom
element
host
cell
dyshac
could
introduc
sever
type
patient
stem
progenitor
cell
ex
vivo
therapi
eg
induc
pluripot
stem
cell
mesoangioblast
mesenchym
stem
cell
one
main
issu
howev
translat
stem
cell
therapi
muscl
disord
develop
success
nonvir
gene
deliveri
system
skelet
muscl
highli
depend
proport
muscl
innerv
motoneuron
cell
need
transfect
year
research
test
anim
model
human
trial
gear
us
toward
two
type
muscledirect
nonvir
gene
transfer
applic
direct
inject
repres
far
simpler
poorli
effici
approach
provid
highli
activ
gene
product
use
nonvir
gene
therapi
becom
increasingli
amen
infecti
cancer
peripher
ischemia
diseas
vector
could
nake
dna
synthet
complex
intravascular
deliveri
simpl
intraven
perfus
nonvir
vector
today
far
less
practic
region
hydrodynam
deliveri
nake
dna
offer
sever
advantag
viral
vector
hold
potenti
muscl
diseas
includ
limbgirdl
muscular
dystrophi
peripher
neuropathi
nevertheless
muscl
gene
therapi
use
system
administr
nonvir
vector
retain
major
hurdl
need
overcom
human
applic
disclosur
author
declar
potenti
compet
financi
interest
